Stay updated on CABozantinib in NSCLC MET Clinical Trial
Sign up to get notified when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.

Latest updates to the CABozantinib in NSCLC MET Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedA new revision label, v3.6.5, has been applied, replacing the previous v3.6.4. This update appears to be a routine site maintenance or software/version bump and does not indicate changes to the study text, eligibility criteria, or participant information.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4 on the page. It represents a small backend/frontend update without altering displayed study details.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing the previous Revision: v3.6.2. This appears to be a backend or formatting update and does not modify study details or public content.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision updated from v3.6.0 to v3.6.2, indicating a software/content management update to the page rather than changes to study details.SummaryDifference0.0%

- Check74 days agoChange DetectedNew guidance sections were added to the study record (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention/Treatment heading was standardized. Older labels such as Verified and Last known status was: were removed or updated to Revision: v3.6.0, with new fields Last verified and Last known status was added.SummaryDifference1%

- Check81 days agoChange DetectedA new Revision: v3.5.5 was added and the previous Revision: v3.5.4 was removed, indicating a minor update to the page's revision history rather than changes to the study content.SummaryDifference0.0%

Stay in the know with updates to CABozantinib in NSCLC MET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.